Low-dose metronomic chemotherapy: From past experience to new paradigms in the treatment of cancer

David Loven, Erez Hasnis, Francesco Bertolini, Yuval Shaked

Research output: Contribution to journalArticle

Abstract

Low-dose metronomic (LDM) chemotherapy represents an emerging concept in the treatment of cancer. Directed against tumor cells and other types of cells, such as endothelial and immune cells, this treatment regimen alters the tumor microenvironment and suppresses innate features which support tumor growth. Ongoing Phase III clinical studies explore various applications of LDM chemotherapy, mostly combined with other anticancer agents, to act as complementary treatments to conventional maximum tolerated dose (MTD) chemotherapy. In this article we summarize preclinical and clinical experience with LDM chemotherapy, emphasizing the potential contribution of this new treatment modality to future paradigms in the systemic treatment of patients with cancer.

Original languageEnglish
Pages (from-to)193-201
Number of pages9
JournalDrug Discovery Today
Volume18
Issue number3-4
DOIs
Publication statusPublished - Feb 2013

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Low-dose metronomic chemotherapy: From past experience to new paradigms in the treatment of cancer'. Together they form a unique fingerprint.

  • Cite this